Intelligent Bio Solutions awaits FDA clearance for its fingerprint drug test, aiming for a 2025 U.S. launch and expanding its presence in the multi-billion market.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Intelligent Bio Solutions reports rising sales and profit margins, driven by recurring revenue from cartridge sales and global expansion through key partnerships.
Intelligent Bio Solutions stock surges with increased trading volume, driven by progress on its FDA 510(k) submission. The company, specializing in non-invasive testing, advances clinical trials and reports significant growth in drug screening system installations.
INBS stock results show that Intelligent Bio Solutions beat analyst estimates for earnings per share but missed on revenue for the third quarter of 2024.
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions.
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.
